Clinical Trial Update: Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome [Phase 2]

View source ↗

Summary

The update covers the Phase 2 clinical trial of Gemlapodect (NOE-105) for Tourette Syndrome in adults and adolescents, focusing on efficacy and safety. The stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tourette Syndrome

Drugs mentioned

• Gemlapodect (NOE-105) (NOE-105)

Snippet

Sponsor: Noema Pharma AG | Conditions: Tourette Syndrome | Phase 2 | Status: ACTIVE_NOT_RECRUITING